BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 288 filers reported holding BIO-TECHNE CORP in Q3 2016. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,154,824 | -3.9% | 31,656 | +15.3% | 0.02% | 0.0% |
| Q2 2023 | $2,241,397 | +13.3% | 27,458 | +3.0% | 0.02% | +5.9% |
| Q1 2023 | $1,978,054 | +89852.4% | 26,662 | +0.5% | 0.02% | -10.5% |
| Q4 2022 | $2,199 | -99.9% | 26,533 | +362.3% | 0.02% | +18.8% |
| Q3 2022 | $1,630,000 | -17.7% | 5,739 | +0.5% | 0.02% | -23.8% |
| Q2 2022 | $1,980,000 | -13.0% | 5,712 | +8.7% | 0.02% | -4.5% |
| Q1 2022 | $2,276,000 | -10.8% | 5,257 | +6.6% | 0.02% | -18.5% |
| Q4 2021 | $2,552,000 | +8.0% | 4,932 | +1.2% | 0.03% | 0.0% |
| Q3 2021 | $2,362,000 | -59.5% | 4,874 | -62.4% | 0.03% | -58.5% |
| Q2 2021 | $5,834,000 | +18.0% | 12,956 | +0.1% | 0.06% | +6.6% |
| Q1 2021 | $4,944,000 | +20.8% | 12,944 | +0.4% | 0.06% | +5.2% |
| Q4 2020 | $4,094,000 | +33.7% | 12,893 | +4.4% | 0.06% | -3.3% |
| Q3 2020 | $3,061,000 | +43.4% | 12,355 | +52.8% | 0.06% | +50.0% |
| Q2 2020 | $2,135,000 | +25.6% | 8,086 | -9.8% | 0.04% | +2.6% |
| Q1 2020 | $1,700,000 | +15.2% | 8,966 | +33.4% | 0.04% | +50.0% |
| Q4 2019 | $1,476,000 | +12.6% | 6,722 | +0.3% | 0.03% | +13.0% |
| Q3 2019 | $1,311,000 | -5.8% | 6,702 | +0.4% | 0.02% | -4.2% |
| Q2 2019 | $1,391,000 | +5.3% | 6,674 | +0.3% | 0.02% | +4.3% |
| Q1 2019 | $1,321,000 | +37.7% | 6,653 | +0.4% | 0.02% | +21.1% |
| Q4 2018 | $959,000 | -38.7% | 6,627 | -13.6% | 0.02% | -13.6% |
| Q3 2018 | $1,565,000 | +4.3% | 7,666 | -24.4% | 0.02% | +10.0% |
| Q2 2018 | $1,501,000 | -1.6% | 10,142 | +0.4% | 0.02% | -4.8% |
| Q1 2018 | $1,526,000 | +115.2% | 10,104 | +84.6% | 0.02% | +110.0% |
| Q4 2017 | $709,000 | +7.8% | 5,472 | +0.5% | 0.01% | 0.0% |
| Q3 2017 | $658,000 | +2.8% | 5,446 | -0.1% | 0.01% | 0.0% |
| Q2 2017 | $640,000 | +15.5% | 5,449 | -0.0% | 0.01% | +11.1% |
| Q1 2017 | $554,000 | -2.5% | 5,450 | -1.3% | 0.01% | -18.2% |
| Q4 2016 | $568,000 | -6.0% | 5,524 | +0.1% | 0.01% | -8.3% |
| Q3 2016 | $604,000 | -25.2% | 5,517 | -23.0% | 0.01% | -20.0% |
| Q2 2016 | $808,000 | +28.7% | 7,163 | +7.7% | 0.02% | +15.4% |
| Q1 2016 | $628,000 | -35.3% | 6,648 | -38.3% | 0.01% | -35.0% |
| Q4 2015 | $970,000 | -2.2% | 10,783 | +0.5% | 0.02% | -16.7% |
| Q3 2015 | $992,000 | -6.1% | 10,730 | -0.0% | 0.02% | +26.3% |
| Q2 2015 | $1,057,000 | +8.7% | 10,734 | +10.8% | 0.02% | +11.8% |
| Q1 2015 | $972,000 | +32.2% | 9,691 | +21.9% | 0.02% | +54.5% |
| Q4 2014 | $735,000 | – | 7,953 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |